Select a date & time
October 2024
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
|
29
|
30
|
1
|
2
|
3
|
4
|
5
|
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
|
29
|
30
|
31
|
1
|
2
|
November 2024
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
|
27
|
28
|
29
|
30
|
31
|
1
|
2
|
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
December 2024
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
|
29
|
30
|
31
|
1
|
2
|
3
|
4
|
January 2025
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
|
29
|
30
|
31
|
1
|
2
|
3
|
4
|
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
|
27
|
28
|
29
|
30
|
31
|
1
|
Description
mRNA (messenger RNA) screening as candidate for vaccines.
CleaScrip™ Custom mRNA (Low dsRNA)
Top-notch mRNAs characterized by Yeasen's low dsRNA levels and exceptional integrity are indispensable for disease research utilizing mRNA tools and the advancement of RNA therapeutics.
https://www.yeabio.com/pages/cleascrip%E2%84%A2-mrna-synthesis-low-dsrna
Due to the ability of dsRNA to signal through Toll-like receptors TLR3 and RLR-mediated pathways, it is crucial to control the dsRNA content during clinical research. In primary cells and stem cells, the presence of dsRNA-binding receptors will inevitably trigger an immune response.
Yeasen offers exceptional control over the dsRNA content in mRNA.
In conventional mRNA synthesis services do not include a step for dsRNA removal. Adding this step increases costs, making the product more expensive. Typically, mRNA is categorized into RUO (Research Use Only) grade and preclinical grade, with dsRNA content being a key distinguishing factor. Yeasen Biotechnology, through collaboration with third parties and the use of the CleaScrip™ T7 RNA polymerase, can provide mRNA with ultra-low dsRNA content for drug or vaccine development scientists from the outset. This enables researchers to access near-clinical-grade quality mRNA at a lower cost from the very beginning.
mRNA
Our exclusive mRNA manufacturing process relies on CleaScrip™ T7 RNA Polymerase, enabling the production of high-quality mRNAs with remarkably low dsRNA content (approximately 1/100000), coupled with numerous customizable features.
A Comprehensive Solution for CleaScrip™ mRNA Production
Our mRNA production service simplifies your process from protein sequence to LNP delivery. Our expert team guarantees the excellence and expression effectiveness of your mRNA, offering a seamless, all-in-one solution.
mRNA holds several unique properties that are advantageous in the development of new therapies, including highly localized expression patterns, rapid development time, and a high degree of safety as a non-genome editing substrate for therapies.
Yeasen's custom mRNA production with superior purity, 3 month timeline.
Yeasen mRNA services can help to streamline the vaccine and drug development process and accelerate the translation of targets into practical therapies by helping to smooth the transition from early research and development to GMP mRNA manufacturing.
Request A Quote from Gentaur
Contact Our Expert Lieven Gevaert Bio-ir. RUG 1996
- Superior mRNA Quality
- Built-in CE test to guarantee mRNA quality
- Guaranteed LNP particle size and uniformity
- Comprehensive QC tests panel